Imatinib, the first line of treatment for CML, inhibits BCR-ABL (breakpoint cluster region-Abelson) tyrosine kinase activity by blocking the ATP-binding site [2]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.